Dainippon Sumitomo Drops U.S. Bipolar In Favor Of Schizophrenia Drug
This article was originally published in PharmAsia News
Executive SummaryDainippon Sumitomo Pharma of Japan is looking to a schizophrenia drug now in Phase III trials in the United States as its product with the best potential. The decision means de-emphasizing its Lonasen (blonanserin) drug for treating bipolar disorder, which had been in Phase II U.S. trials. The schizophrenia drug, lurasidone, had been in trials at the same time as Lonasen, but the company said slower sales for last year caused it to suspend one of the trials. With the change in plans, the firm anticipates being able to supply more data to the U.S. FDA to ensure approval. (Click here for more - a subscription may be required
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.